Open AccessLong noncoding RNA CERS6‐AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA
Author(s) -
Bao Gang,
Huang Jianjun,
Pan Wei,
Li Xing,
Zhou Tian
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2675
Subject(s) - cancer research , carcinogenesis , apoptosis , malignancy , long non coding rna , breast cancer , messenger rna , metastasis , cell growth , biology , cancer , rna , medicine , gene , genetics
Breast cancer (BC) leads to the highest mortality in women worldwide, characterized by inevitable proliferation and metastasis of BC cells. Mounting evidence confirm that lncRNAs play a significant role in the tumorigenesis and development of BC. lncRNA CERS6‐AS1 is a novel discovery, and its role and molecular mechanism in BC has not been studied. In this study, it was discovered that CERS6‐AS1 was overexpressed in BC tissues and cells. CERS6‐AS1 accelerated cell proliferation and suppressed cell apoptosis in BC. Moreover, molecular mechanism exploration uncovered that there was a positive association between CERS6 and CERS6‐AS1 (or IGF2BP3) expression in BC. Furthermore, IGF2BP3 serves as a RNA‐binding protein for CERS6‐AS1 and CERS6‐AS1 promoted CERS6 mRNA stability by binding to IGF2BP3. In the end, rescue experiments verified that overexpression of CERS6 rescues the inhibition of CERS6‐AS1 deficiency on BC progression in vitro and vivo. Taken together, these evidences suggested that CERS6‐AS1 promoted the progression of BC by binding to IGF2BP3 and thus enhancing the stability of CERS6 mRNA, providing a new underlying therapeutic target for BC to improve prognosis.